HIT Consultant February 16, 2024
Syed Hamza Sohail

What You Should Know:

  • Proscia, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq® AP-Dx*. The digital pathology solution was cleared for the purpose of primary diagnosis.
  • Proscia’s Concentriq AP-Dx is a comprehensive diagnostic software solution that immerses pathologists in an intuitive experience for viewing, interpreting, and managing whole slide images and helps to drive confidence and efficiency gains. It can also streamline collaboration, broadening access to expertise. Concentriq AP-Dx was designed to be used in clinical settings of all sizes, from individual reference laboratories to the largest hospital systems. In support of its 510(k) clearance, Proscia conducted a multi-site clinical study...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Provider, Technology
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns
HHS Explores Stronger FDA Oversight for Food Ingredients

Share This Article